These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 3702062

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Clinical studies with cefoperazone in the biliary disease].
    Morinaga T, Furukawa M, Nakata T, Yamada R, Itoh S, Maeda S, Itose K, Ohtsubo M.
    Jpn J Antibiot; 1985 Jan; 38(1):128-32. PubMed ID: 3989972
    [Abstract] [Full Text] [Related]

  • 8. [Pharmacokinetics of cefoperazone in end-stage renal failure patients on peritoneal dialysis].
    Okuda T, Katoh T, Takaichi K, Matsunaga H, Uchida S, Kurokawa K, Nihei H.
    Jpn J Antibiot; 1986 Oct; 39(10):2775-9. PubMed ID: 3806960
    [Abstract] [Full Text] [Related]

  • 9. [Fundamental and clinical studies of sulbactam/cefoperazone in the pediatric field].
    Iwata S, Sato Y, Iwasaki Y, Hayano S, Wakabayashi R, Kojima Y, Akita H, Sunakawa K, Oikawa T, Osano M.
    Jpn J Antibiot; 1984 Oct; 37(10):1831-45. PubMed ID: 6094863
    [Abstract] [Full Text] [Related]

  • 10. [Clinical laboratory approach for estimating effective administrative dose of cefoperazone. Evaluation of disc susceptibility test and its interpretation system].
    Matsuo K, Uete T.
    Jpn J Antibiot; 1988 Oct; 41(10):1418-29. PubMed ID: 3204655
    [Abstract] [Full Text] [Related]

  • 11. [Basic and clinical evaluation of sulbactam/cefoperazone in the field of pediatrics].
    Toyonaga Y, Kurosu Y, Nakamura H, Sugita M, Takahashi T, Hori M.
    Jpn J Antibiot; 1984 Dec; 37(12):2457-77. PubMed ID: 6098740
    [Abstract] [Full Text] [Related]

  • 12. [A study of prostatic tissue levels of cefoperazone].
    Yoshida H, Hoshino M, Haraguchi C, Ogawa Y, Kawai N, Sakurai H, Ishihara Y, Higaki Y, Imamura K.
    Hinyokika Kiyo; 1985 May; 31(5):871-4. PubMed ID: 2413746
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Clinical laboratory approach for estimating effective administrative dose of sulbactam/cefoperazone].
    Uete T, Matsuo K.
    Jpn J Antibiot; 1988 Nov; 41(11):1578-90. PubMed ID: 3210296
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. [Clinical evaluation of sulbactam/cefoperazone in lower respiratory tract infections].
    Ishibashi T, Takamoto M, Shinoda A, Yoshida M, Ichikawa Y, Kido M, Ninomiya K, Kitahara Y, Hara N, Tsurutani H.
    Jpn J Antibiot; 1990 Feb; 43(2):239-56. PubMed ID: 2194054
    [Abstract] [Full Text] [Related]

  • 19. [Laboratory and clinical studies of sulbactam/cefoperazone in the pediatric field].
    Nishimura T, Tabuki K, Takashima T, Takagi M.
    Jpn J Antibiot; 1984 Oct; 37(10):1880-92. PubMed ID: 6094866
    [Abstract] [Full Text] [Related]

  • 20. [Fundamental and clinical studies of sulbactam/cefoperazone in the field of pediatrics].
    Nakazawa S, Sato H, Narita A, Nakazawa S, Suzuki H, Chikaoka H, Tazoe K.
    Jpn J Antibiot; 1984 Nov; 37(11):2174-87. PubMed ID: 6098710
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.